We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 07, 2022

Efficacy of Sacituzumab Govitecan in Patients With HR+/HER2− MBC by HER2 IHC Status

Annals of Oncology

 

Additional Info

Annals of Oncology
214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
Ann. Oncol 2022 Sep 01;33(suppl 7)S635-S636, P Schmid, J Cortés, F Marmé, et al

Further Reading